Avalo Therapeutics grants Rita Jain 1,322 stock options

A director's options were fully vested when granted and issued in lieu of Board fees under the non-employee director compensation plan.

Rhea-AI Filing Summary

Avalo Therapeutics, Inc. director Rita Jain received a grant of 1,322 stock options on September 30, 2026. The options were 100% vested and were issued under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees. The report lists a transaction price of $12.29 per share and an exercise price of $15.33 per share. The options expire September 30, 2036, and Jain's reported position after the transaction was 1,322 options.

Insider Trade Summary

Grant/Award: 1,322 shares

Grant/Award 1 txn

Insider Jain Rita

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F2, F1	1,322	$12.29	$16K

Holdings After Transaction: Stock Option (Right to Buy) — 1,322 contracts (Direct)

Footnotes (2)

1. F1. The options were granted on September 30, 2026, and are 100% vested.
2. F2. The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.

Key Figures

Options granted: 1,322 options Options held after transaction: 1,322 options Reported transaction price: $12.29 per share +3 more

6 metrics

Options granted 1,322 options Granted September 30, 2026

Options held after transaction 1,322 options Reported position following the transaction

Reported transaction price $12.29 per share Option grant reported September 30, 2026

Exercise price $15.33 per share Stock options granted September 30, 2026

Vesting 100% Options granted September 30, 2026

Expiration date September 30, 2036 Stock options

Key Terms

Stock Option (Right to Buy), exercise price, vested, Amended and Restated Non-Employee Director Compensation Plan

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vested financial

"100% vested"

Amended and Restated Non-Employee Director Compensation Plan financial

"pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did AVTX director Rita Jain receive?

Rita Jain received 1,322 stock options on September 30, 2026. They were 100% vested, had a $15.33-per-share exercise price, and expire September 30, 2036. The options were issued under the Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:16 PM Accepted by SEC EDGAR 10/02/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Rita

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.33	09/30/2026		A		1,322		(1)	09/30/2036	Common Stock	1,322	$12.29(2)	1,322	D

Explanation of Responses:

1. The options were granted on September 30, 2026, and are 100% vested.

2. The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.

	/s/ Christopher Sullivan, Attorney-in-Fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)